BioNote, Inc. (KRX:377740)
South Korea · Delayed Price · Currency is KRW 4,835.00
-5.00 (-0.10%)
At close: Aug 21, 2026
BioNote Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 489,260 | 554,446 | 480,684 | 433,228 | 874,096 | - | |
Market Cap Growth | -15.32% | 15.35% | 10.95% | -50.44% | - | - |
Enterprise Value | 124,197 | 207,970 | 83,431 | 16,432 | 174,842 | - |
Last Close Price | 4835.00 | 5242.42 | 4330.73 | 3729.89 | 7538.85 | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | 8.70 | - | 2.84 | - |
PS Ratio | 3.87 | 4.69 | 4.68 | 4.81 | 1.82 | - |
PB Ratio | 0.32 | 0.37 | 0.29 | 0.28 | 0.55 | - |
P/TBV Ratio | 0.32 | 0.37 | 0.30 | 0.28 | 0.55 | - |
P/FCF Ratio | 11.76 | 88.43 | 10.13 | - | 4.23 | - |
P/OCF Ratio | 10.74 | 38.55 | 8.30 | - | 3.51 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.98 | 1.76 | 0.81 | 0.18 | 0.37 | - |
EV/EBITDA Ratio | 4.07 | 7.99 | 4.09 | - | 0.58 | - |
EV/EBIT Ratio | 6.02 | 12.37 | 6.83 | - | 0.59 | - |
EV/FCF Ratio | 2.98 | 33.17 | 1.76 | - | 0.85 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Debt / EBITDA Ratio | 0.11 | 0.14 | 0.19 | - | 0.00 | 0.00 |
Debt / FCF Ratio | 0.08 | 0.58 | 0.08 | - | 0.01 | 0.00 |
Net Debt / Equity Ratio | -0.23 | -0.22 | -0.24 | -0.25 | -0.45 | -0.38 |
Net Debt / EBITDA Ratio | -11.96 | -12.91 | -19.68 | 10.14 | -2.39 | -1.03 |
Net Debt / FCF Ratio | -8.77 | -53.61 | -8.46 | 48.46 | -3.48 | -1.00 |
Asset Turnover | 0.08 | 0.07 | 0.06 | 0.05 | 0.30 | 0.53 |
Inventory Turnover | 1.96 | 2.00 | 1.86 | 1.86 | 1.94 | 1.87 |
Quick Ratio | 17.03 | 28.69 | 18.20 | 39.35 | 14.94 | 4.84 |
Current Ratio | 18.54 | 31.01 | 19.69 | 42.26 | 16.66 | 5.42 |
Return on Equity (ROE) | -7.79% | -5.56% | 3.46% | -1.30% | 21.43% | 70.80% |
Return on Assets (ROA) | 0.77% | 0.65% | 0.46% | -1.76% | 11.38% | 25.01% |
Return on Invested Capital (ROIC) | 1.74% | 1.40% | 0.77% | -4.62% | 26.34% | 59.77% |
Return on Capital Employed (ROCE) | 1.30% | 1.10% | 0.70% | -3.00% | 17.30% | 34.20% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -25.69% | -15.78% | 11.50% | -4.73% | 35.21% | - |
FCF Yield | 8.50% | 1.13% | 9.87% | -1.88% | 23.66% | - |
Payout Ratio | - | - | 36.94% | - | 16.23% | 7.38% |
Buyback Yield / Dilution | 0.69% | 0.73% | 0.02% | -8.16% | -0.64% | -0.14% |